Skip to main content
Clinical Trials/DRKS00009247
DRKS00009247CompletedNot Applicable

ZARAMulticentre, non-interventional study of the efficacy and safety of zoledronic acid in skeletal related tumors (SRE) and hypercalcemia of malignancy (TIH) - ZARA

AxioNovo Gmbh0 sites495 target enrollmentStarted: August 18, 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
495

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to one (—)
Sex
All

Inclusion Criteria

  • 18 Years old
  • - Informed consent was singed correctly
  • - Patient has advanced tumor disease which extended to the skeletal or elevated calcium serum levels as a result of malignant tumor growth
  • -Therapeutic decision was made independently from a possible NIS enrollment
  • - Patient does not participate in a clinical trial

Exclusion Criteria

  • - Contraindications to the use of zoledronic acid according to the SmPC.
  • - The current therapy was started more than 12 weeks ago.
  • - The patient is participating in a clinical trial at the same time.
  • - Pregnancy is present or the patient is breastfeeding.

Investigators

Similar Trials